Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Florencia M. McAllister

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9915-0943; OpenAlex author ID A5047609850; NIH RePORTER profile ID 9794660. Sources: funder_awards.

Their work

Papers
49 (first author 5, last author 13)
Trials
3 (principal investigator on 3)
Grants
4
Labs led
1
Collaborators
184
Papers, trials and grants by year

2012: 1 paper, 1 grant · 2013: none · 2014: 4 papers, 1 grant · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 5 papers · 2020: 6 papers · 2021: 10 papers, 1 trial · 2022: 4 papers · 2023: 2 papers, 1 trial · 2024: 4 papers · 2025: 2 papers, 1 grant · 2026: 7 papers, 1 trial, 1 grant

Papers 49

  1. Lack of tumor-derived LCN2 sensitizes pancreatic cancer cells to ferroptosis induction. Co-author DOI 10.1016/j.canlet.2026.218823↗
  2. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  3. Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4733↗
  4. Exercise Modulates Microbial Metabolites and Induces Stromal Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-5143↗
  5. Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. Co-author DOI 10.1158/2767-9764.crc-25-0777↗
  6. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  7. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  8. Fatty pancreas on EUS: Risk factors, correlation with CT/MRI, and implications for pancreatic cancer screening. Co-author DOI 10.1097/eus.0000000000000109↗
  9. New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-24-570↗
  10. Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals: an opportunity not to be missed Last author DOI 10.1016/j.gie.2024.12.001↗
  11. The liver casts a wide NET for metastatic pancreatic cancer. First author DOI 10.1038/s41591-024-03112-5↗
  12. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  13. Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment. First author DOI 10.1158/1078-0432.ccr-23-3295↗
  14. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2553↗
  15. Bacterial and fungal characterization of pancreatic adenocarcinoma from Endoscopic Ultrasound-guided biopsies. Last author DOI 10.3389/fimmu.2023.1268376↗
  16. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.05.006↗
  17. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice. Last author DOI 10.1016/j.path.2022.05.004↗
  18. Implementation of a Video-based Remote Germline Testing for Individuals With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2022.03.026↗
  19. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  20. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Last author DOI 10.1002/cam4.3870↗
  21. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Co-author DOI 10.1038/s41374-020-00490-5↗
  22. Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer Co-author DOI 10.1038/s41374-021-00615-4↗
  23. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine Co-author DOI 10.1101/2021.11.29.470415↗
  24. Therapeutic potential of microbial modulation in pancreatic cancer. First author DOI 10.1136/gutjnl-2019-319807↗
  25. Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste". Last author DOI 10.1158/1078-0432.ccr-18-0900↗
  26. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Co-author DOI 10.1158/1940-6207.capr-20-0642↗
  27. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  28. Hyperpolarized Magnetic Resonance and Artificial Intelligence: Frontiers of Imaging in Pancreatic Cancer. Co-author DOI 10.2196/26601↗
  29. The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies? Co-author DOI 10.3390/ijms22189914↗
  30. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.3229↗
  31. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  32. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Last author DOI 10.1084/jem.20190354↗
  33. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Co-author DOI 10.1093/carcin/bgz116↗
  34. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0224↗
  35. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Last author DOI 10.4103/eus.eus_56_19↗
  36. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. Co-author DOI 10.1016/j.ccell.2019.11.004↗
  37. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Last author DOI 10.1016/j.cell.2019.07.008↗
  38. Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. Co-author DOI 10.1021/acs.jproteome.9b00132↗
  39. Pancreatic Cancer Early Detection and Interception in an Atypical Case of Peutz-Jeghers Syndrome Last author DOI 10.1097/mpa.0000000000001293↗
  40. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIR… First author DOI 10.1097/mpa.0000000000001345↗
  41. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Last author DOI 10.1158/1940-6207.capr-18-0014↗
  42. Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. Last author DOI 10.1158/2159-8290.cd-18-0123↗
  43. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Co-author DOI 10.1007/s00262-017-2053-4↗
  44. Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. Co-author PMID 28656024↗
  45. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.09.050↗
  46. Targeting IL-17 for pancreatic cancer prevention. Co-author DOI 10.18632/oncotarget.2618↗
  47. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 t… Co-author DOI 10.4161/cbt.28413↗
  48. Immune cells in pancreatic cancer: Joining the dark side. First author DOI 10.4161/onci.29125↗
  49. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9818-6↗

Trials 3

  1. Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening Principal investigator NCT07513116↗
  2. Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection Principal investigator NCT05873699↗
  3. Fecal Microbial Transplants for the Treatment of Pancreatic Cancer Principal investigator NCT04975217↗

Grants 4

  1. Interrogating the Spatial and Functional Relevance of Microbes in Pancreatic Cancer and Metastasis R01CA282786↗
  2. Dissecting the Source and Mechanisms of IL-17-Mediated Modulation of Pancreatic Tumorigenesis R37CA237384↗
  3. Targeting IL-17 Signaling Axis in Pancreatic Ductal Adenocarcinoma AWARD pancan:2014-florencia-mcallister-md-targeting-il-17-signaling-axis-in-pancre
  4. Role of Inflammatory Cells in Early Pancreatic Tumorigenesis AWARD pancan:2012-florencia-mcallister-md-role-of-inflammatory-cells-in-early-panc

Closest collaborators

The 25 strongest of 184 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 22 shared papers, 2014–2026 · strength 2.94
  2. Matthew H. G. Katz · 10 shared papers, 2018–2026 · strength 1.30
  3. Erika Yanil Faraoni · 5 shared papers, 2021–2026 · strength 1.29
  4. Manoop S. Bhutani · 7 shared papers, 2017–2025 · strength 1.14
  5. Michael P. Kim · 8 shared papers, 2019–2025 · strength 0.98
  6. Jennifer M. Bailey · 7 shared papers, 2014–2026 · strength 0.88
  7. Maureen E. Mork · 5 shared papers, 2018–2024 · strength 0.85
  8. Vidhi Chandra · 6 shared papers, 2019–2026 · strength 0.85
  9. Chirayu Mohindroo · 5 shared papers, 2020–2025 · strength 0.78
  10. Eugene Jon Koay · 5 shared papers, 2019–2026 · strength 0.73
  11. David R. Fogelman · 6 shared papers, 2018–2026 · strength 0.69
  12. Robert A. Wolff · 5 shared papers, 2020–2026 · strength 0.65
  13. Riccardo Ballarò · 3 shared papers, 2026 · strength 0.62
  14. Robin D. Wright · 3 shared papers, 2023–2026 · strength 0.62
  15. Shubham Pant · 4 shared papers, 2020–2026 · strength 0.55
  16. Ana De Jesus‐Acosta · 3 shared papers, 2020–2025 · strength 0.54
  17. An Ngo‐Huang · 3 shared papers, 2022–2026 · strength 0.54
  18. Nathan H. Parker · 3 shared papers, 2022–2026 · strength 0.54
  19. Keri Schadler · 3 shared papers, 2022–2026 · strength 0.54
  20. Sumedha Pareek · 3 shared papers, 2022–2026 · strength 0.54
  21. Maria Q. B. Petzel · 3 shared papers, 2022–2026 · strength 0.54
  22. Michael James Overman · 4 shared papers, 2020–2026 · strength 0.54
  23. Samir Hanash · 3 shared papers, 2019–2026 · strength 0.50
  24. Kanchan Singh · 4 shared papers, 2021–2023 · strength 0.46
  25. Nirav C Thosani · 4 shared papers, 2021–2023 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.